MET ALTERATION

Clinical trials for MET ALTERATION explained in plain language.

Never miss a new study

Get alerted when new MET ALTERATION trials appear

Sign up with your email to follow new studies for MET ALTERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug cocktail aims to outsmart lung cancer resistance

Disease control Not yet recruiting

This study tests two experimental drugs, ANS014004 and PLB1004, given together to people with a specific type of advanced lung cancer (EGFR mutation-positive NSCLC). The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing, especially…

Matched conditions: MET ALTERATION

Phase: PHASE1, PHASE2 • Sponsor: Beijing Pearl Biotechnology Limited Liability Company • Aim: Disease control

Last updated Jun 27, 2026 08:04 UTC

MET ALTERATION

Get alerted when new MET ALTERATION trials appear

New drug cocktail aims to outsmart lung cancer resistance